“…Our team recently published an in-depth analysis of the comprehensive cost and utilization of commercial CAR-T therapy in pediatric B-ALL patients with commercial insurance in the United States [ 3 ]. The analysis specifically focuses on a cohort of 37 patients, aged 1–25, who underwent CAR-T cell infusion between October 2016 and December 2021.…”